BioSpace News Archive

Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (NASDAQ:SYRE), a biotechnology company advancing a pipeline of investigational antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease (“IBD”), today announced its fourth quarter and full year 2023 financial results and provided program and corporate updates.

BioLife Solutions, Inc. (Nasdaq: BLFS) (“BioLife” or the “Company”) today announced financial results for the fourth quarter and year ended December 31, 2023, and introduces 2024 revenue guidance.

DermTech, Inc., a leader in precision dermatology enabled by a non-invasive skin genomics technology, reported its fourth-quarter 2023 financial results.

Therapeutic Solutions International, Inc. (TSOI), announced today results of ongoing experiments demonstrating that the healing effects of JadiCells appear to be mediated by a biological mechanism involving interplay between two types of immunological cells found in the body.

Exactech Quality Control Manager Wesley Garrett experienced a full circle moment in both his professional and personal life when his father received an Activit-E™ polyethylene insert after following the company’s polyethylene initiatives for six years.

Anthropocene Institute Hosts Fusion Energy Panel at SXSW.

Cell MedX Corp. (OTC Pink: CMXC) (“Cell MedX”, or the “Company”) a biotech company focusing on the discovery, development and commercialization of therapeutic

Zenith Epigenetics Ltd. (“Zenith” or the “Company”) announces its support of Rare Disease Day by highlighting our expanded development efforts of BET inhibitor ZEN-3694

BeiGene Announces New Efficacy Analysis Comparing BRUKINSA ® vs Acalabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia.

Incyte announced the launch of The Unseen Journey, a program that brings to life the hidden emotional and physical toll of myeloproliferative neoplasms, a group of rare, chronic and progressive blood cancers.